Oculis Shares Fall After Decision To Not Pursue FDA Approval For Eye Disease Treatment

Dow Jones

May 30

By Christopher Kuo

Oculis Holding shares plunged after the company said it does not plan to pursue a regulatory filing with the Food and Drug Administration for its proposed treatment for an eye disease.

Shares of the biopharmaceutical company fell 23% to $22.71 Friday. Despite the intraday decline, the stock was up 14% year to date.

The company's decision not to file with the FDA comes after key primary and secondary endpoints were not met in its Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema, a complication from diabetes that can cause vision loss or blindness.

Chief Executive Riad Sherif said the company is "naturally disappointed" with the results form the trials.

"We will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease," Sherif said.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

May 29, 2026 16:08 ET (20:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2639781672"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2639781672\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2639781672?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-30 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2639781672","market":"other","top_or_hot":-1,"title":"Oculis Shares Fall After Decision To Not Pursue FDA Approval For Eye Disease Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding shares plunged after the company said it does not plan to pursue a regulatory filing with the Food and Drug Administration for its proposed treatment for an eye disease. \n</p>\n<p>\n  Shares of the biopharmaceutical company fell 23% to $22.71 Friday. Despite the intraday decline, the stock was up 14% year to date. \n</p>\n<p>\n  The company's decision not to file with the FDA comes after key primary and secondary endpoints were not met in its Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema, a complication from diabetes that can cause vision loss or blindness. \n</p>\n<p>\n  Chief Executive Riad Sherif said the company is \"naturally disappointed\" with the results form the trials. \n</p>\n<p>\n  \"We will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease,\" Sherif said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 16:08 ET (20:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Shares Fall After Decision To Not Pursue FDA Approval For Eye Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Shares Fall After Decision To Not Pursue FDA Approval For Eye Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-30 04:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding shares plunged after the company said it does not plan to pursue a regulatory filing with the Food and Drug Administration for its proposed treatment for an eye disease. \n</p>\n<p>\n  Shares of the biopharmaceutical company fell 23% to $22.71 Friday. Despite the intraday decline, the stock was up 14% year to date. \n</p>\n<p>\n  The company's decision not to file with the FDA comes after key primary and secondary endpoints were not met in its Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema, a complication from diabetes that can cause vision loss or blindness. \n</p>\n<p>\n  Chief Executive Riad Sherif said the company is \"naturally disappointed\" with the results form the trials. \n</p>\n<p>\n  \"We will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease,\" Sherif said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 29, 2026 16:08 ET (20:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2639781672","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2639781672","pubTimestamp":1780085280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Oculis Holding shares plunged after the company said it does not plan to pursue a regulatory filing with the Food and Drug Administration for its proposed treatment for an eye disease.Shares of the biopharmaceutical company fell 23% to $22.71 Friday. Despite the intraday decline, the stock was up 14% year to date.The company's decision not to file with the FDA comes after key primary and secondary endpoints were not met in its Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema, a complication from diabetes that can cause vision loss or blindness.Chief Executive Riad Sherif said the company is \"naturally disappointed\" with the results form the trials.\"We will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease,\" Sherif said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","OCS":"Oculis"},"translate_title":"Oculis决定不寻求FDA批准眼病治疗后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"OCS":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\nOculis Holding shares plunged after the company said it does not plan to pursue a regulatory filing with the Food and Drug Administration for its proposed treatment for an eye disease. \n\n\n  Shares of the biopharmaceutical company fell 23% to $22.71 Friday. Despite the intraday decline, the stock was up 14% year to date. \n\n\n  The company's decision not to file with the FDA comes after key primary and secondary endpoints were not met in its Phase 3 trials of OCS-01 eye drops in patients with diabetic macular edema, a complication from diabetes that can cause vision loss or blindness. \n\n\n  Chief Executive Riad Sherif said the company is \"naturally disappointed\" with the results form the trials. \n\n\n  \"We will strategically focus resources on advancing our late-stage portfolio, including the Privosegtor platform, starting with the PIONEER program for Privosegtor in optic neuropathies, and the PREDICT-1 trial for Licaminlimab to drive precision medicine in dry eye disease,\" Sherif said. \n\n\n \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 29, 2026 16:08 ET (20:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}